🕵️ Vistagen Therapeutics, Inc. ($VTGN)
SEC insider & ownership activity, last 12 months · CIK 1411685 · every row links its SEC filing
Insiders were quiet over the last 12 months – no open-market buys or sells. 2 red-flag 8-Ks in the window, most recently Delisting notice (3.01), Aug 4, 2026.
Insider flow
0 buyers, $0 (0 lots) · 0 sellers, $0 (0 lots)
No open-market insider transactions in the last 12 months.
5%+ holders
| Holder | Stake | Class | Schedule | Event | |
|---|---|---|---|---|---|
| Janus Henderson Biotech Innovation Master Fund Ltd | 11.7% | 13G | Sep 8, 2025 | filing ↗ | |
| BVF Partners L P/IL | 10.0% | 13G | Feb 14, 2025 | filing ↗ | |
| BVF INC/IL | 10.0% | 13G | Feb 14, 2025 | filing ↗ | |
| Mark N. Lampert | 10.0% | 13G | Feb 14, 2025 | filing ↗ | |
| Commodore Capital LP | 9.9% | 13G | Aug 14, 2026 | filing ↗ | |
| Commodore Capital Master LP | 9.9% | 13G | Aug 14, 2026 | filing ↗ | |
| Robert Egen Atkinson | 9.9% | 13G | Aug 14, 2026 | filing ↗ | |
| Michael Kramarz | 9.9% | 13G | Aug 14, 2026 | filing ↗ | |
| BVF GP Holdings LLC | 9.4% | 13G | Feb 14, 2025 | filing ↗ | |
| Chen Yu | 6.7% | 13G | Aug 14, 2026 | filing ↗ | |
| Biotechnology Value Fund L P | 5.4% | 13G | Feb 14, 2025 | filing ↗ | |
| BVF I GP LLC | 5.4% | 13G | Feb 14, 2025 | filing ↗ | |
| TCG Crossover GP II, LLC | 5.1% | 13G | Aug 14, 2026 | filing ↗ | |
| TCG Crossover Fund II, L.P. | 5.1% | 13G | Aug 14, 2026 | filing ↗ |
Planned insider sales (Form 144)
No sale notices filed in the last 12 months.
Material events (8-K)
| Item | Event date | |
|---|---|---|
| Shareholder vote (5.07) | Sep 10, 2026 | filing ↗ |
| Financial Statements and Exhibits (9.01) | Sep 10, 2026 | filing ↗ |
| Earnings (2.02) | Aug 14, 2026 | filing ↗ |
| Financial Statements and Exhibits (9.01) | Aug 14, 2026 | filing ↗ |
| Reg FD disclosure (7.01) | Aug 6, 2026 | filing ↗ |
| Other events (8.01) | Aug 6, 2026 | filing ↗ |
| Financial Statements and Exhibits (9.01) | Aug 6, 2026 | filing ↗ |
| Delisting notice (3.01) | Aug 4, 2026 | filing ↗ |
| Officer/director changes (5.02) | Jul 29, 2026 | filing ↗ |
| Reg FD disclosure (7.01) | Jul 29, 2026 | filing ↗ |
| Financial Statements and Exhibits (9.01) | Jul 29, 2026 | filing ↗ |
| Reg FD disclosure (7.01) | Jun 30, 2026 | filing ↗ |
| Other events (8.01) | Jun 30, 2026 | filing ↗ |
| Financial Statements and Exhibits (9.01) | Jun 30, 2026 | filing ↗ |
| Officer/director changes (5.02) | Jun 16, 2026 | filing ↗ |
| Earnings (2.02) | Jun 15, 2026 | filing ↗ |
| Financial Statements and Exhibits (9.01) | Jun 15, 2026 | filing ↗ |
| Other events (8.01) | Jun 9, 2026 | filing ↗ |
| Financial Statements and Exhibits (9.01) | Jun 9, 2026 | filing ↗ |
| Officer/director changes (5.02) | May 18, 2026 | filing ↗ |
| Reg FD disclosure (7.01) | May 18, 2026 | filing ↗ |
| Financial Statements and Exhibits (9.01) | May 18, 2026 | filing ↗ |
| Other events (8.01) | May 12, 2026 | filing ↗ |
| Financial Statements and Exhibits (9.01) | May 12, 2026 | filing ↗ |
| Other events (8.01) | May 8, 2026 | filing ↗ |
| Financial Statements and Exhibits (9.01) | May 8, 2026 | filing ↗ |
| Other events (8.01) | Apr 22, 2026 | filing ↗ |
| Financial Statements and Exhibits (9.01) | Apr 22, 2026 | filing ↗ |
| Officer/director changes (5.02) | Apr 7, 2026 | filing ↗ |
| Delisting notice (3.01) | Apr 1, 2026 | filing ↗ |